Receipt of R&D Tax Incentive
Filed with ASX · · 2 pages · English
Earlier from AdAlta
- AdAlta secures licensing deal with GE Healthcare
- Executive team changes
- GLP toxicology study commences
- Entitlement Offer Results and Shortfall Notification
- Completion of Capital Raise - $5 million
Later from AdAlta
- Tim Oldham Appointed as Chief Executive Officer
- GLP Toxicology study results
- AdAlta awarded Biomedical Translation Bridge Funding
- AD-214 Phase I strategy and timing update
- AdAlta Granted US Patent for AD-214
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta